Pfizer Push For COVID Vaccine EUA In Ages 5-11 Includes School, Mental Health Arguments

 
• By Derrick Gingery

Briefing documents for the upcoming advisory committee tout potential ‘indirect’ benefits and argue that lower dose should address myocarditis concerns.

Children playing in a school yard
Pfizer wrote in briefing documents that vaccinating children age 5 to 11 could help alleviate educational disruption caused by COVID-19 outbreaks in schools.

More from US FDA Performance Tracker

More from Regulatory Trackers